Arnhem, the Netherlands, May 16, 2007 — Akzo Nobel today announced that Dr. Jörg Spiekerkötter, CFO and member of the Board of Management of its subsidiary, Organon BioSciences N.V., will leave the company.
This development comes in the wake of the March 12 announcement that Akzo Nobel intends to sell Organon BioSciences to the U.S.-based pharmaceutical company Schering-Plough.
. Spiekerkötter joined Organon BioSciences N.V. on November 1, 2006, in anticipation of the planned IPO of Akzo Nobel’s Pharma businesses. Previously he was a member of the Executive Board and CFO of Schering AG.
on the departure, Organon BioSciences CEO Toon Wilderbeek said: “We would like to thank Jörg for his professional and dedicated services to the company and wish him all the best for the future.”
. Wilderbeek will continue to lead Organon BioSciences until the deal is closed.